Search results - 4 results
Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.
Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen ...
Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.
Publication Type: Peer reviewed scientific article Authors: N Dauby; Lucy Catteau; Joris Hautekiet; Marion Montourcy; E Bottieau; Goetghebeur, E; Dominique Van Beckhoven Source: Int J Antimicrob Agents (2020) Health Topics: COVID-19 Service: Épidémiolog ...
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants
investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for ...
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study.
with older age, non-white race, underweight body mass index, and CF-related diabetes. Prescription of highly effective CFTR modulator therapies was associated with a significantly reduced odds of being ...